Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in ...

Hereditary hemorrhagic telangiectasia (HHT) can be fatal. However, it does not affect the average life expectancy of most people. Complications can occur when blood vessels rupture in vital organs.

Medical imaging, like MRI, CT, and ultrasound, plays a vital role in diagnosing HHT, formerly known as Osler-Weber-Rendu syndrome. Imaging can help guide treatment and improve your outlook with HHT.

Most people with this condition live a full, typical life, but it can be life threatening if a blood vessel ruptures in an internal organ and bleeds uncontrollably. Osler-Weber-Rendu syndrome, which ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

A repurposed cancer drug eases the frequent nosebleeds and other symptoms of a hereditary disease of the blood vessels 1. There is no approved therapy specifically for hereditary haemorrhagic ...

A clinical trial led by Dr. Keith McCrae of Cleveland Clinic has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT). The ...

A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in ...